Login / Signup

Budget impact and cost per responder analysis of upadacitinib for the treatment of moderate to severe atopic dermatitis from the perspective of the social security and the private sector in Argentina.

Natalia EspinolaFederico Rodriguez CairoliCarlos Rojas-RoquePaula Carolina LunaDiego KanevskyValeria MigliazzaAndrés Pichon-Riviere
Published in: Expert review of pharmacoeconomics & outcomes research (2024)
The introduction of upadacitinib in MS-AD treatment was associated with modest savings for the social security and private payer budget in Argentina.
Keyphrases
  • healthcare
  • mental health
  • atopic dermatitis
  • health insurance
  • mass spectrometry
  • multiple sclerosis
  • ms ms
  • high intensity